Drugs / Ga-68 PSMA-HBED-CC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03822845 | Mar 2019 → Mar 2021 | castration-resistant prostate carcinoma | Michael Graham PhD, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT03388346 | Feb 2018 → Jul 2021 | castration-resistant prostate carcinoma | Michael Graham PhD, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT03389451 | Feb 2018 → Jul 2019 | prostate cancer | Michael Graham PhD, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ga-68 PSMA-HBED-CC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03388346 ↗ |
| Modality | Diagnostic / imaging agent | “investigational PET drug (radionuclide)” NCT03388346 ↗ |
| Route | Intravenous | “administered intravenously” NCT03388346 ↗ |